Increase in both angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis

Pathologie Biologie

Volumn 62, Issue 6, 2014, Pages 391-394

  Smadja, D M ^a,b,c   Nunes, H ^d   Juvin, K ^c   Bertil, S ^c   Valeyre, D ^d   Gaussem, P ^a,b,c   Israel Biet, D ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Fondation Carpentier   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

Angiogenesis; Idiopathic pulmonary fibrosis; SCF; TSP 1; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOSTATIC PROTEIN; STEM CELL FACTOR; THROMBOSPONDIN 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANK SUM TEST; TOTAL LUNG CAPACITY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY;

AGED; ANGIOGENESIS INDUCING AGENTS; ANGIOSTATIC PROTEINS; CASE-CONTROL STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; STEM CELL FACTOR; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84910018415     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2014.07.006     Document Type: Article

References (29)

1. Noble P.W., Albera C., Bradford W.Z., Costabel U., Glassberg M.K., Kardatzke D., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (capacity): two randomised trials. Lancet 2011, 377(9779):1760-1769.
2. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
3. Ebina M., Shimizukawa M., Shibata N., Kimura Y., Suzuki T., Endo M., et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004, 169(11):1203-1208.
4. Farkas L., Gauldie J., Voelkel N.F., Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011, 45(1):1-15.
5. Smadja D.M., Mauge L., Nunes H., d'Audigier C., Juvin K., Borie R., et al. Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosis. Angiogenesis 2013, 16(1):147-157.
6. Evrard S.M., D'Audigier C., Mauge L., Israel-Biet D., Guerin C.L., Bieche I., et al. The profibrotic cytokine transforming growth factor-beta1 increases endothelial progenitor cell angiogenic properties. J Thromb Haemost 2012, 10(4):670-679.
7. Ding L., Dolgachev V., Wu Z., Liu T., Nakashima T., Wu Z., et al. Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis. J Pathol 2013, 230(2):205-214.
8. Gambaryan N., Perros F., Montani D., Cohen-Kaminsky S., Mazmanian M., Renaud J.F., et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J 2011, 37(6):1392-1399.
9. Montani D., Perros F., Gambaryan N., Girerd B., Dorfmuller P., Price L.C., et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011, 184(1):116-123.
10. Nathan S.D., Shlobin O.A., Weir N., Ahmad S., Kaldjob J.M., Battle E., et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011, 140(1):221-229.
11. Hamada K., Nagai S., Tanaka S., Handa T., Shigematsu M., Nagao T., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007, 131(3):650-656.
12. Ide M., Ishii H., Mukae H., Iwata A., Sakamoto N., Kadota J., et al. High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia. Respir Med 2008, 102(11):1625-1630.
13. Azuma A., Li Y.J., Abe S., Usuki J., Matsuda K., Henmi S., et al. Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin. Am J Respir Cell Mol Biol 2005, 32(2):93-98.
14. Kuhn C., Mason R.J. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995, 147(6):1759-1769.
15. Lawler P.R., Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012, 2(5):a006627.
16. Qin Q., Qian J., Ge L., Shen L., Jia J., Jin J., et al. Effect and mechanism of thrombospondin-1 on the angiogenesis potential in human endothelial progenitor cells: an in vitro study. PLoS One 2014, 9(2):e88213.
17. Smadja D.M., D'Audigier C., Bieche I., Evrard S., Mauge L., Dias J.V., et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 2011, 31(3):551-559.
18. Yehualaeshet T., O'Connor R., Green-Johnson J., Mai S., Silverstein R., Murphy-Ullrich J.E., et al. Activation of rat alveolar macrophage-derived latent transforming growth factor-beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999, 155(3):841-851.
19. Ando M., Miyazaki E., Ito T., Hiroshige S., Nureki S.I., Ueno T., et al. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 2010, 188(3):247-252.
20. Simler N.R., Brenchley P.E., Horrocks A.W., Greaves S.M., Hasleton P.S., Egan J.J. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004, 59(7):581-585.
21. Malli F., Koutsokera A., Paraskeva E., Zakynthinos E., Papagianni M., Makris D., et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. PLoS One 2013, 8(1):e53658.
22. Cosgrove G.P., Brown K.K., Schiemann W.P., Serls A.E., Parr J.E., Geraci M.W., et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004, 170(3):242-251.
23. Meyer K.C., Cardoni A., Xiang Z.Z. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med 2000, 135(4):332-338.
24. Farkas L., Farkas D., Ask K., Moller A., Gauldie J., Margetts P., et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009, 119(5):1298-1311.
25. Hamada N., Kuwano K., Yamada M., Hagimoto N., Hiasa K., Egashira K., et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005, 175(2):1224-1231.
26. Takahashi H., Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005, 109(3):227-241.
27. Wygrecka M., Dahal B.K., Kosanovic D., Petersen F., Taborski B., Von Gerlach S., et al. Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-alpha/Raf-1/p44/42 signaling pathway. Am J Pathol 2013, 182(6):2094-2108.
28. Da Silva C.A., Adda M., Stern M., De Blay F., Frossard N., Israel-Biet D. Marked stem cell factor expression in the airways of lung transplant recipients. Respir Res 2006, 7:90.
29. Smadja D., Gaussem P., Roncal C., Fischer A.M., Emmerich J., Darnige L. Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus 2010, 19(7):837-843.